{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:37:58Z","timestamp":1792514278194,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40263-025-01251-y","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:17:30Z","timestamp":1764573450000},"page":"199-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer\u2019s Disease: Synthesis of Evidence from Observational and Interventional Trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Susan","family":"Abushakra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Murali","family":"Doraiswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Barakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Petrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Patrick","family":"Kesslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Porsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"McSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merce","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earvin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Bracoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"McLaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean F.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abe","family":"Durrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"2","key":"1251_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1251_CR2","doi-asserted-by":"crossref","first-page":"e70235","DOI":"10.1002\/alz.70235","volume":"21","author":"Alzheimer\u2019s Association 2025","year":"2025","unstructured":"Alzheimer\u2019s Association 2025. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2025;21(4):e70235.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1251_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00570","volume":"22","author":"JL Cummings","year":"2025","unstructured":"Cummings JL. Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer\u2019s disease: strategies and research directions. Neurotherapeutics. 2025;22(3):e00570.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"1251_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1251_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"key":"1251_CR6","doi-asserted-by":"publisher","first-page":"91524","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:91524.","journal-title":"JAMA Neurol"},{"issue":"10","key":"1251_CR7","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, et al. The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5481\u2013503.","journal-title":"Mol Psychiatry"},{"key":"1251_CR8","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1251_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer\u2019s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685\u201391.","journal-title":"J Magn Reson Imaging"},{"issue":"11","key":"1251_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.neurobiolaging.2008.01.010","volume":"30","author":"J Barnes","year":"2009","unstructured":"Barnes J, Bartlett JW, van de Pol LA, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer\u2019s disease. Neurobiol Aging. 2009;30(11):1711\u201323.","journal-title":"Neurobiol Aging"},{"key":"1251_CR11","doi-asserted-by":"publisher","first-page":"1390574","DOI":"10.3389\/fnagi.2024.1390574","volume":"16","author":"M Woodward","year":"2024","unstructured":"Woodward M, Bennett DA, Rundek T, et al. The relationship between hippocampal changes in healthy aging and Alzheimer\u2019s disease: a systematic literature review. Front Aging Neurosci. 2024;16:1390574.","journal-title":"Front Aging Neurosci"},{"key":"1251_CR12","first-page":"4","volume":"11","author":"H Zhu","year":"2022","unstructured":"Zhu H, Mehta M, Huang SM, et al. Toward bridging unmet need in early AD: an evaluation of beta-amyloid plaque burden as a potential drug development tool. Clin Pharmacol Ther. 2022;11:4.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1251_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12382","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y. An insider\u2019s perspective on FDA approval of aducanumab. Alzheimers Dement (NY). 2023;9(2):e12382.","journal-title":"Alzheimers Dement (NY)"},{"key":"1251_CR14","unstructured":"US Food and Drug Administration (FDA). Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease. Draft guidance for industry, Center for Drug Evaluation and Research (CDER), 2024. Docket: FDA-2013-D-0077."},{"key":"1251_CR15","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1002\/alz.14306","volume":"20","author":"T Schaap","year":"2024","unstructured":"Schaap T, Thropp P, Tosun D, Alzheimer\u2019s Disease Neuroimaging Initiative. Timing of Alzheimer\u2019s disease biomarker progressions: a two-decade observational study from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2024;20:9060\u20137.","journal-title":"Alzheimers Dement"},{"key":"1251_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neurobiolaging.2022.10.015","volume":"124","author":"Y Stern","year":"2023","unstructured":"Stern Y, Albert M, Barnes CA, et al. A framework for concepts of reserve and resilience in aging. Neurobiol Aging. 2023;124:100\u20133.","journal-title":"Neurobiol Aging"},{"key":"1251_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.14283\/jpad.2024.54","volume":"11","author":"W Yang","year":"2024","unstructured":"Yang W, Wang J, Guo J, et al. Association of cognitive reserve indicator with cognitive decline and structural brain differences in middle and older age: findings from the UK Biobank. J Prev Alzheimer\u2019s Dis. 2024;11:739\u201348.","journal-title":"J Prev Alzheimer's Dis"},{"key":"1251_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobe on MRI in probable Alzheimer\u2019s disease and normal aging, diagnostic value and neuropsychological correlates. J Neurol, Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"issue":"8925","key":"1251_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","volume":"344","author":"MJ West","year":"1994","unstructured":"West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer\u2019s disease. Lancet. 1994;344(8925):769\u201372.","journal-title":"Lancet"},{"issue":"4","key":"1251_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/(SICI)1096-9861(19970324)379:4<482::AID-CNE2>3.0.CO;2-Z","volume":"379","author":"G Simi\u0107","year":"1997","unstructured":"Simi\u0107 G, Kostovi\u0107 I, Winblad B, Bogdanovi\u0107 N. Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer\u2019s disease. J Comp Neurol. 1997;379(4):482\u201394.","journal-title":"J Comp Neurol"},{"issue":"9","key":"1251_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.neurobiolaging.2003.12.005","volume":"25","author":"MJ West","year":"2004","unstructured":"West MJ, Kawas CH, Stewart WF, et al. Hippocampal neurons in pre-clinical Alzheimer\u2019s disease. Neurobiol Aging. 2004;25(9):1205\u201312.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"1251_CR22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/hbm.20934","volume":"31","author":"SG Mueller","year":"2010","unstructured":"Mueller SG, Schuff N, Yaffe K, et al. Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer\u2019s disease. Hum Brain Mapp. 2010;31(9):1339\u201347.","journal-title":"Hum Brain Mapp"},{"key":"1251_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052727","volume":"25","author":"M Tolar","year":"2024","unstructured":"Tolar M, Hey JA, Power A, Abushakra S. The single toxin origin of Alzheimer\u2019s disease and other neurodegenerative disorders enables targeted approach to treatment and prevention. Int J Mol Sci. 2024;25:2727.","journal-title":"Int J Mol Sci"},{"key":"1251_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s43587-025-00810-8","volume":"5","author":"E Andersson","year":"2025","unstructured":"Andersson E, Lindblom N, Janelidze S, et al. Soluble cerebral A\u03b2 protofibrils link A\u03b2 plaque pathology to changes in CSF A\u03b242\/A\u03b240 ratios, neurofilament light and tau in Alzheimer\u2019s disease model mice. Nat Aging. 2025;5:366\u201375.","journal-title":"Nat Aging"},{"key":"1251_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14415","volume":"21","author":"R Cacciaglia","year":"2025","unstructured":"Cacciaglia R, Falc\u00f3n C, Benavides GS, et al. Soluble A\u03b2 pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer\u2019s continuum: evidence across two independent cohorts. Alzheimers Dement. 2025;21:e14415.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1251_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1212\/WNL.55.4.484","volume":"55","author":"CR Jack Jr","year":"2000","unstructured":"Jack CR Jr, Petersen RC, Xu YC, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55(4):484\u20139.","journal-title":"Neurology"},{"issue":"3","key":"1251_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer\u2019s disease neuroimaging initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201\u20139.","journal-title":"Neurology"},{"issue":"2","key":"1251_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/mrm.1910080210","volume":"8","author":"JP Seab","year":"1988","unstructured":"Seab JP, Jagust WJ, Wong ST, et al. Quantitative NMR measurements of hippocampal atrophy in Alzheimer\u2019s disease. Magn Reson Med. 1988;8(2):200\u20138.","journal-title":"Magn Reson Med"},{"issue":"1","key":"1251_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1212\/WNL.41.1.51","volume":"41","author":"JP Kesslak","year":"1991","unstructured":"Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer\u2019s disease. Neurology. 1991;41(1):51\u20134.","journal-title":"Neurology"},{"issue":"3","key":"1251_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1251_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1251_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jalz.2014.05.1756","volume":"11","author":"GB Frisoni","year":"2015","unstructured":"Frisoni GB, Jack CR Jr, Bocchetta M, et al. The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement. 2015;11(2):111\u201325.","journal-title":"Alzheimers Dement"},{"key":"1251_CR33","unstructured":"European Medicines Agency (EMA) Qualification opinion of low hippocampal volume (atrophy) by MRI for use in regulatory clinical trials \u2013 In pre-dementia stage of Alzheimer\u2019s disease, 2011. EMA\/879297\/2011."},{"issue":"4","key":"1251_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jalz.2013.07.003","volume":"10","author":"DLG Hill","year":"2014","unstructured":"Hill DLG, Schwarz AJ, Isaac M, et al. Coalition against major diseases\/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(4):421-429.e3.","journal-title":"Alzheimers Dement"},{"key":"1251_CR35","unstructured":"European Medicines Agency (EMA) guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease, 2018. Reference no. CPMP\/EWP\/553\/95 Rev.2."},{"key":"1251_CR36","unstructured":"US Food and Drug Administration (FDA). Accelerated approval\u2014Expedited Program for Serious Conditions. Center for Drug Evaluation and Research (CDER, Draft Guidance). 2024. Docket: FDA-2024-D-2033."},{"issue":"5","key":"1251_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3988\/jcn.2024.0176","volume":"20","author":"M Bailey","year":"2024","unstructured":"Bailey M, Ilchovska ZG, Hosseini AA, Jung J. Impact of apolipoprotein E \u03b54 in Alzheimer\u2019s disease: a meta-analysis of voxel-based morphometry studies. J Clin Neurol. 2024;20(5):469\u201377.","journal-title":"J Clin Neurol"},{"issue":"7","key":"1251_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70413","volume":"21","author":"MT Rosbergen","year":"2025","unstructured":"Rosbergen MT, van der Veere P, Claus JJ, et al. Subcortical gray matter volumes and 5-year dementia risk in individuals with subjective cognitive decline or mild cognitive impairment: a multi-cohort analysis. Alzheimers Dement. 2025;21(7):e70413.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1251_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jalz.2015.01.001","volume":"11","author":"LG Apostolova","year":"2017","unstructured":"Apostolova LG, Zarow C, Biado K, et al. EADC-ADNI Working Group on the Harmonized Protocol for Manual Hippocampal Segmentation. Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement. 2015;11(2):139\u201350.","journal-title":"Alzheimers Dement"},{"key":"1251_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.nicl.2017.04.020","volume":"15","author":"AE Blanken","year":"2017","unstructured":"Blanken AE, Hurtz S, Zarow C, et al. Associations between hippocampal morphometry and neuropathologic markers of Alzheimer\u2019s disease using 7 T MRI. Neuroimage Clin. 2017;15:56\u201361.","journal-title":"Neuroimage Clin."},{"issue":"1","key":"1251_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13(1):80 (Erratum in: Alzheimers Res Ther. 2022;14(1):70).","journal-title":"Alzheimers Res Ther"},{"key":"1251_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1251_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd-Haeberlein","year":"2022","unstructured":"Budd-Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis."},{"key":"1251_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"issue":"18","key":"1251_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"11","key":"1251_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40265-025-02250-5","volume":"85","author":"S Abushakra","year":"2025","unstructured":"Abushakra S, Power A, Watson D, et al. Clinical efficacy, safety and imaging effects of oral valiltramiprosate in APOE\u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: results of the phase III, randomized, double-blind, placebo-controlled, 78-week APOLLOE4 trial. Drugs. 2025;85(11):1455\u201372.","journal-title":"Drugs"},{"issue":"84","key":"1251_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","volume":"2024","author":"JA Hey","year":"2024","unstructured":"Hey JA, Abushakra S, Blennow K, et al. Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of a 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease. Drugs. 2024;(84):811\u201323.","journal-title":"Drugs"},{"key":"1251_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","volume":"31","author":"P Kocis","year":"2017","unstructured":"Kocis P, Tolar M, Yu J, et al. Elucidating the A\u03b242 anti-aggregation mechanism of action of tramiprosate in Alzheimer\u2019s disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31:495\u2013509.","journal-title":"CNS Drugs"},{"issue":"32","key":"1251_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","volume":"2018","author":"JA Hey","year":"2018","unstructured":"Hey JA, Kocis P, Hort J, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018;2018(32):849\u201361 (Correction in: CNS Drugs. 2018;32;1185).","journal-title":"CNS Drugs"},{"key":"1251_CR50","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1021\/acs.jctc.9b00599","volume":"15","author":"C Liang","year":"2019","unstructured":"Liang C, Savinov SN, Fejzo J, et al. Modulation of amyloid-\u03b242 conformation by small molecules through nonspecific binding. J Chem Theory Comput. 2019;15:5169\u201374.","journal-title":"J Chem Theory Comput"},{"key":"1251_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jconrel.2025.01.019","volume":"379","author":"D Shastri","year":"2025","unstructured":"Shastri D, Raorane CJ, Raj V, Lee S. Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-\u03b2 aggregation and mitigates cognitive decline in Alzheimer\u2019s disease. J Control Release. 2025;379:390\u2013408.","journal-title":"J Control Release"},{"key":"1251_CR52","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202402622R","volume":"39","author":"D Muramatsu","year":"2025","unstructured":"Muramatsu D, Watanabe-Nakayama T, Tsuji M, et al. ALZ-801 prevents amyloid \u03b2-protein assembly and reduces cytotoxicity: a preclinical experimental study. FASEB J. 2025;39:e70382.","journal-title":"FASEB J"},{"issue":"20","key":"1251_CR53","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N Engl J Med. 2023;389(20):1862\u201376.","journal-title":"N Engl J Med"},{"issue":"2","key":"1251_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14414","volume":"21","author":"T Bittner","year":"2025","unstructured":"Bittner T, Tonietto M, Klein G, et al. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement. 2025;21(2):e14414.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1251_CR55","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113\u201321.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1251_CR56","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.neuroimage.2008.10.037","volume":"44","author":"JS Wonderlick","year":"2009","unstructured":"Wonderlick JS, Ziegler DA, Hosseini-Varnamkhasti P, et al. Reliability of MRI-derived cortical and subcortical morphometric measures: effects of pulse sequence, voxel geometry, and parallel imaging. Neuroimage. 2009;44(4):1324\u201333.","journal-title":"Neuroimage"},{"key":"1251_CR57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.neuroimage.2017.05.019","volume":"156","author":"O Potvin","year":"2017","unstructured":"Potvin O, Dieumegarde L, Duchesne S, Alzheimer\u2019s Disease Neuroimaging Initiative. Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain. Neuroimage. 2017;156:315\u201339.","journal-title":"Neuroimage"},{"issue":"1","key":"1251_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0169-2607(97)01803-8","volume":"53","author":"PA Freeborough","year":"1997","unstructured":"Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed. 1997;53(1):15\u201325.","journal-title":"Comput Methods Programs Biomed"},{"key":"1251_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12498","volume":"10","author":"S Abushakra","year":"2024","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, et al. APOLLOE4 phase 3 study of oral ALZ-801\/valiltramiprosate in APOE\u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease: trial design & baseline characteristics. Alzheimers Dement (N Y). 2024;10:e12498.","journal-title":"Alzheimers Dement (N Y)."},{"key":"1251_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12117","volume":"6","author":"S Abushakra","year":"2020","unstructured":"Abushakra S, Porsteinsson AP, Sabbagh M, et al. APOE \u03b54\/\u03b54 homozygotes with early Alzheimer\u2019s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimers Dement (N Y). 2020;6:e12117.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1251_CR61","doi-asserted-by":"publisher","first-page":"595","DOI":"10.14283\/jpad.2023.50","volume":"10","author":"SP Dickson","year":"2023","unstructured":"Dickson SP, Wessels AM, Dowsett SA, et al. Time saved as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J Prev Alzheimers Dis. 2023;10:595\u20139.","journal-title":"J Prev Alzheimers Dis"},{"key":"1251_CR62","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1002\/alz.14035","volume":"20","author":"G Wang","year":"2024","unstructured":"Wang G, Cutter G, Oxtoby NP, et al. Statistical considerations when estimating time-saving treatment effects in Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2024;20:5421\u201333.","journal-title":"Alzheimers Dement"},{"key":"1251_CR63","doi-asserted-by":"crossref","unstructured":"Yu, J, Geerts H, Short SM, et al. Valiltramiprosate.ALZ-801 prevents hippocampal atrophy and clinical decline in a stage 2 AD subpopulation in APOLLOE4 phase 3 study. 2025 AAIC poster no. 108565 (27\u201331 July, Toronto, Canada).","DOI":"10.1002\/alz70861_108565"},{"key":"1251_CR64","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.nicl.2013.07.006","volume":"3","author":"TM Nir","year":"2013","unstructured":"Nir TM, Jahanshad N, Villalon-Reina JE, et al. Effectiveness of DTI measures in distinguishing AD, MCI and normal aging. Neuroimage Clin. 2013;3:180\u201393.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"1251_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0132-3","volume":"7","author":"PS Weston","year":"2015","unstructured":"Weston PS, Simpson IJ, Ryan NS, et al. Diffusion imaging changes in grey matter in Alzheimer\u2019s disease: a potential marker of early neurodegeneration. Alzheimers Res Ther. 2015;7(1):47.","journal-title":"Alzheimers Res Ther"},{"key":"1251_CR66","doi-asserted-by":"crossref","unstructured":"Parker CS, Weston PSJ, Zhang H, et al. White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer\u2019s disease: evidence from data-driven disease progression modelling. BioRxiv 2022; preprint.","DOI":"10.1101\/2022.07.12.499784"},{"key":"1251_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.793991","volume":"14","author":"M Bergamino","year":"2022","unstructured":"Bergamino M, Schiavi S, Daducci A, et al. Analysis of brain structural connectivity networks and white matter integrity in patients with mild cognitive impairment. Front Aging Neurosci. 2022;14:793991.","journal-title":"Front Aging Neurosci"},{"key":"1251_CR68","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves F, Kalinowski P, Ayton S. Accelerated brain volume loss caused by anti-\u03b2-amyloid drugs: a systematic review and meta-analysis. Neurology. 2023;100:e2114\u201324.","journal-title":"Neurology"},{"key":"1251_CR69","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1474-4422(24)00335-1","volume":"23","author":"CRS Belder","year":"2024","unstructured":"Belder CRS, Boche D, Nicoll JAR, et al. Brain volume change following anti-amyloid \u03b2 immunotherapy for Alzheimer\u2019s disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol. 2024;23:1025\u201334.","journal-title":"Lancet Neurol"},{"key":"1251_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.14283\/jpad.2023.92","volume":"11","author":"M Ten Kate","year":"2024","unstructured":"Ten Kate M, Barkhof F, Schwarz AJ. Consistency between treatment effects on clinical and brain atrophy outcomes in Alzheimer\u2019s disease trials. J Prev Alzheimers Dis. 2024;11:38\u201347.","journal-title":"J Prev Alzheimers Dis"},{"issue":"16","key":"1251_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"2020","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease\u2014one peptide, two pathways. Nat Rev Neurol. 2020;2020(16):30\u201342.","journal-title":"Nat Rev Neurol"},{"key":"1251_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"1251_CR73","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2165\/00023210-200014060-00004","volume":"14","author":"PM Doraiswamy","year":"2000","unstructured":"Doraiswamy PM, Chen JG, Charles HC. Brain magnetic resonance spectroscopy. CNS Drugs. 2000;14:457\u201372.","journal-title":"CNS Drugs"},{"issue":"6 Suppl","key":"1251_CR74","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.3174\/ajnr.A3944","volume":"35","author":"F Gao","year":"2014","unstructured":"Gao F, Barker BP. Various MRS application tools for Alzheimer disease and mild cognitive impairment. AJNR Am J Neuroradiol. 2014;35(6 Suppl):S4-11.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"S6","key":"1251_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/alz.066333","volume":"18","author":"SI Thomopoulos","year":"2022","unstructured":"Thomopoulos SI, Nir TM, Villalon Reina JE, et al. Effects of dementia and MCI on diffusion tensor metrics using the updated ADNI3 DTI preprocessing pipeline. Alzheimers Dement. 2022;18(S6):e066333.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1251_CR76","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3233\/JAD-231416","volume":"99","author":"M Nakaya","year":"2024","unstructured":"Nakaya M, Sato N, Matsuda H, et al. Assessment of gray matter microstructural alterations in Alzheimer\u2019s disease by free water imaging. J Alzheimers Dis. 2024;99(4):1441\u201353.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1251_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jagp.2023.08.002","volume":"32","author":"JA Silva-Rudberg","year":"2024","unstructured":"Silva-Rudberg JA, Salardini E, O\u2019Dell RS, et al. Assessment of gray matter microstructure and synaptic density in Alzheimer\u2019s disease: a multimodal imaging study with DTI and SV2A PET. Am J Geriatr Psychiatry. 2024;32(1):17\u201328.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"1251_CR78","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jamaneurol.2014.1482","volume":"71","author":"K Kantarci","year":"2014","unstructured":"Kantarci K, Schwarz CG, Reid RI, et al. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. JAMA Neurol. 2014;71(12):1547\u201354.","journal-title":"JAMA Neurol"},{"key":"1251_CR79","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","volume":"269","author":"G Giacomucci","year":"2022","unstructured":"Giacomucci G, Mazzeo S, Bagnoli S, et al. Plasma NfL chain as a biomarker of AD in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022;269:4270\u201380.","journal-title":"J Neurol"},{"issue":"1","key":"1251_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16089","volume":"31","author":"S Mazzeo","year":"2024","unstructured":"Mazzeo S, Ingannato A, Giacomucci G, et al. Plasma neurofilament light chain predicts Alzheimer\u2019s disease in patients with subjective cognitive decline and mild cognitive impairment: a cross-sectional and longitudinal study. Eur J Neurol. 2024;31(1):e16089.","journal-title":"Eur J Neurol"},{"key":"1251_CR81","doi-asserted-by":"crossref","unstructured":"Liang E, Abushakra S, Doraiswamy M. Valiltramiprosate effects on grey and white matter microstructural integrity in APOE4\/4 homozygotes with early AD and their correlations to clinical outcomes: MRI mean diffusivity results from the 78-week APOLLOE4 phase 3 trial. Poster no. 874, AAIC 2025 (27\u201331 July, Toronto, Canada).","DOI":"10.1002\/alz70861_108716"},{"key":"1251_CR82","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cortex.2014.04.006","volume":"57","author":"W Li","year":"2014","unstructured":"Li W, Antuono PG, Xie C, et al. Aberrant functional connectivity in Papez circuit correlates with memory performance in cognitively intact middle-aged APOE4 carriers. Cortex. 2014;57:167\u201376.","journal-title":"Cortex"},{"key":"1251_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102173","volume":"93","author":"PF H\u00f8ilund-Carlsen","year":"2024","unstructured":"H\u00f8ilund-Carlsen PF, Alavi A, Barrio JR, et al. Revision of Alzheimer\u2019s diagnostic criteria or relocation of the Potemkin village. Ageing Res Rev. 2024;93:102173.","journal-title":"Ageing Res Rev"},{"issue":"9","key":"1251_CR84","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJMp2110468","volume":"385","author":"GC Alexander","year":"2021","unstructured":"Alexander GC, Knopman DS, Emerson SS, et al. Revisiting FDA approval of aducanumab. N Engl J Med. 2021;385(9):769\u201371.","journal-title":"N Engl J Med"},{"issue":"3","key":"1251_CR85","doi-asserted-by":"publisher","first-page":"fcac109","DOI":"10.1093\/braincomms\/fcac109","volume":"4","author":"V Planche","year":"2022","unstructured":"Planche V, Manjon JV, Mansencal B, et al. Structural progression of Alzheimer\u2019s disease over decades: the MRI staging scheme. Brain Commun. 2022;4(3):fcac109.","journal-title":"Brain Commun"},{"issue":"8","key":"1251_CR86","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/archneurol.2011.167","volume":"68","author":"MR Sabuncu","year":"2011","unstructured":"Sabuncu MR, Desikan RS, Sepulcre J, Alzheimer\u2019s Disease Neuroimaging Initiative, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68(8):1040\u20138.","journal-title":"Arch Neurol"},{"issue":"2","key":"1251_CR87","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209626","volume":"103","author":"Y Xia","year":"2024","unstructured":"Xia Y, Dore V, Fripp J, et al. Association of basal forebrain atrophy with cognitive decline in early Alzheimer disease. Neurology. 2024;103(2):e209626.","journal-title":"Neurology"},{"issue":"1","key":"1251_CR88","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1038\/s41598-024-78308-3","volume":"14","author":"L Borne","year":"2024","unstructured":"Borne L, Thienel R, Lupton MK, et al. The interplay of age, gender and amyloid on brain and cognition in mid-life and older adults. Sci Rep. 2024;14(1):27207.","journal-title":"Sci Rep"},{"key":"1251_CR89","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.nicl.2016.05.017","volume":"11","author":"CG Schwarz","year":"2016","unstructured":"Schwarz CG, Gunter JL, Wiste HJ, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer\u2019s disease severity. NeuroImage Clin. 2016;11:802\u201312.","journal-title":"NeuroImage Clin"},{"issue":"6","key":"1251_CR90","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503\u201327.","journal-title":"Brain"},{"issue":"12","key":"1251_CR91","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S0006-3223(99)00306-6","volume":"47","author":"MP Laakso","year":"2000","unstructured":"Laakso MP, Frisoni GB, K\u00f6n\u00f6nen M, et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer\u2019s disease: a morphometric MRI study. Biol Psychiatry. 2000;47(12):1056\u201363.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1251_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01319-6","volume":"10","author":"S Raghavan","year":"2022","unstructured":"Raghavan S, Przybelski SA, Reid R, et al. White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathol Commun. 2022;10(1):16.","journal-title":"Acta Neuropathol Commun"},{"key":"1251_CR93","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1002\/alz.14166","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Arani A, Borowski BJ, et al. Overview of ADNI MRI. Alzheimers Dement. 2024;20:7350\u201360.","journal-title":"Alzheimers Dement"},{"issue":"Supp. 2","key":"1251_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/alz.092353","volume":"20","author":"DO Svaldi","year":"2024","unstructured":"Svaldi DO, Rathor S, Cheng YJ, et al. Evaluation of baseline diffusion tensor imaging biomarkers in phase 2 multi-center PROSPECT-ALZ study. Alzheimer\u2019s Dement. 2024;20(Supp. 2):e092353.","journal-title":"Alzheimer\u2019s Dement."},{"key":"1251_CR95","doi-asserted-by":"publisher","first-page":"14014","DOI":"10.1038\/s41598-020-70859-5","volume":"10","author":"A Santuy","year":"2020","unstructured":"Santuy A, Tomas-Roca L, Rodriguez JR, et al. Estimation of the number of synapses in the hippocampus and brain-wide by volume electron microscopy and genetic labeling. Sci Rep. 2020;10:14014.","journal-title":"Sci Rep"},{"key":"1251_CR96","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC. The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:1227\u201333.","journal-title":"Alzheimers Dement"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01251-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01251-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01251-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:03:18Z","timestamp":1769680998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01251-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01251-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All Alzheon employees receive salary compensation and stocks and\/or stock options from Alzheon Inc. The AD experts (Drs. M. Doraiswamy, D. Tosun, A. Porsteinsson, M. Sabbagh, and S. Gauthier) received consulting fees and\/or stock options from Alzheon Inc., and multiple other pharmaceutical companies developing central nervous system (CNS) drugs\/devices\/diagnostic tests; or served on the Alzheon Scientific Advisory Board with stock option compensation. Dr. Doraiswamy has also received grants from several pharmaceutical companies and serves on the boards of health systems and NGOs. Dr. Barkhof received consulting fees from several pharmaceutical companies developing AD treatments and from neuroimaging companies. The clinical trial investigators (Drs. D. Watson, E. MacSweeney, S. Cohen, and M. Boada) received investigator fees for one or all of the cited anti-amyloid drug trials, and for other AD and CNS trials from various global pharmaceutical companies. Dr. J. Barakos consults for Clario Inc., which provides imaging services to Alzheon Inc. and other AD drug trials. Dr. S. Hendrix and S. Dickson and Mr. A. Durrant are employees of Pentara Inc., which provided statistical services, and receive compensation from Alzheon Inc. and other AD trial sponsors. Drs. Petrella and Ritchie do not report any conflicts of interest.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Alzheon Employees: S. Abushakra, J. Hey, P. Kesslak, E. Liang, A. Power, R. McLaine, J. Schaefer. S. Flint, J. Yu, A. Albayrak, M. Brey, and M. Tolar all contributed to the conceptual framework of this paper and to one or more of the following: literature search and summaries, providing data analyses, interpretation, writing, and reviewing or editing the manuscript. S. Abushakra is the principal investigator on the US National Institute of Aging (NIA) grant for the APOLLOE4 trial. Co-authors: P.M. Doraiswamy advised on the design, literature reviews, interpretation, and manuscript editing. D. Tosun contributed to the design and review of MRI and DTI studies and their interpretation. All other co-authors contributed to review of literature, interpretation of studies, and manuscript writing and reviews. D. Watson, E. McSweeney, S. Cohen, and M. Boada were investigators for AD trials (including ALZ-801-AD301) in the USA, UK, Canada, and Europe, respectively; they contributed to data interpretation and manuscript reviews. S. Hendrix, S. Dickson, and A. Durrant contributed to the statistical methods and antibody trial group-level\u00a0analysis. Drs J. Petrella, J. Barakos, C. Ritchie, and S. Gauthier contributed to technical vMRI details, data review and interpretation, and review of the manuscript. All authors have reviewed and approved the final manuscript and agree to be accountable for this work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}